Cited by 289Obstructive Sleep Apnea ResearchHormonal Regulation and HypertensionApelin-related biomedical research

Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report

Open access
Gaddam, K, Pimenta, E, Thomas, S J, Cofield, S S, Oparil, S, Harding, S M, Calhoun, D A·2010·Journal of Human Hypertension

Abstract

Obstructive sleep apnoea (OSA) and hyperaldosteronism are very common in subjects with resistant hypertension. We hypothesized that aldosterone-mediated chronic fluid retention may influence OSA severity in patients with resistant hypertension. We tested this in an open-label evaluation by assessing the changes in the severity of OSA in patients with resistant hypertension after treatment with spironolactone. Subjects with resistant hypertension (clinical blood pressure (BP) >or=140/90 mm Hg on >or=3 antihypertensive medications, including a thiazide diuretic and OSA (defined as an apnoea-hypopnoea index (AHI) >or=15) had full diagnostic, polysomnography before and 8 weeks after spironolactone (25-50 mg a day) was added to their ongoing antihypertensive therapy. In all, 12 patients (mean age 56 years and body mass index 36.8 kg m(-2)) were evaluated. After treatment with spironolactone, the AHI (39.8+/-19.5 vs 22.0+/-6.8 events/h; P<0.05) and hypoxic index (13.6+/-10.8 vs 6.7+/-6.6 events/h; P<0.05), weight and clinic and ambulatory BP were significantly reduced. Plasma renin activity (PRA) and serum creatinine were significantly higher. This study provides preliminary evidence that treatment with a mineralocorticoid receptor antagonist substantially reduces the severity of OSA. If confirmed in a randomized assessment, it will support aldosterone-mediated chronic fluid retention as an important mediator of OSA severity in patients with resistant hypertension.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/jhh.2009.96

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The role of aldosterone in promoting obstructive sleep apnea is additionally supported by studies demonstrating that mineralocorticoid receptor antagonists reduce the severity of obstructive sleep apnea in patients with resistant hypertension.

    “The role of aldosterone in promoting OSA is additionally supported by studies demonstrating that mineralocorticoid receptor antagonists reduce the severity of OSA in patients with RH.280–282”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 26 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Gaddam, K., Pimenta, E., Thomas, S. J., Cofield, S. S., Oparil, S., Harding, S. M., & Calhoun, D. A.
Affiliations
  • Ochsner Medical Center (US)
  • The University of Queensland (AU)
  • University of Alabama at Birmingham (US)
Corresponding author
Calhoun, D A
Venue
Journal of Human Hypertension
Published
2009-12-17
Volume
24
Issue
8
Pages
532-537
ISSN
  • 0950-9240 (ISSN-L)
  • 1476-5527
OpenAlex
W2076462334
Cited by
289
References
26
Citations by year
2026: 10 · 2025: 9 · 2024: 10 · 2023: 13 · 2022: 14 · 2021: 12 · 2020: 17 · 2019: 21 · 2018: 19 · 2017: 16 · 2016: 23 · 2015: 25 · 2014: 33 · 2013: 17 · 2012: 22
FWCI
10.82
Type
journal article
Language
en
Open access
Locations
  • Journal of Human Hypertension (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Heart, Lung, and Blood Institute (R01-HL79040, R01HL079040, R01HL075614, P50HL077100, T32HL007457)
  • National Center for Research Resources (M01RR00032, M01RR000032)
Topics
  • Health Sciences › Medicine › Physiology › Obstructive Sleep Apnea Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
  • Health Sciences › Medicine › Pharmacology › Apelin-related biomedical research
Keywords
spironolactone, obstructive sleep apnea, resistant hypertension, hyperaldosteronism, mineralocorticoid receptor antagonists, aldosterone, fluid retention, apnea-hypopnea index, plasma renin activity, blood pressure
MeSH terms
Blood Pressure, Diuretics, Drug Resistance, Female, Follow-Up Studies, Humans, Hypertension, Male, Middle Aged, Pilot Projects, Severity of Illness Index, Spironolactone, Treatment Outcome, Polysomnography, Sleep Apnea, Obstructive

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review